SCHEMBL13638470

SCHEMBL13638470

C=C1CC(Nc2nccc(-c3ccc(-c4cccc(CO)c4)s3)n2)CC(C)(C)N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.34
BRAF P15056 1/20 0.33
HDAC8 Q9BY41 5/20 0.33
HDAC6 Q9UBN7 4/20 0.33
HDAC1 Q13547 3/20 0.33
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
ABL1 P00519 1/20 0.33
CDK8 P49336 1/20 0.32
MAP3K14 Q99558 2/20 0.32
AKT3 Q9Y243 2/20 0.32
AURKA O14965 1/20 0.32
TTK P33981 1/20 0.32
AURKB Q96GD4 1/20 0.32
INCENP Q9NQS7 1/20 0.32
MAPK14 Q16539 1/20 0.32
MAPK8 P45983 1/20 0.31
MAPK9 P45984 1/20 0.31
MAPK10 P53779 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638514 0.91 IKBKB (0.33) HDAC8IKBKBMAP3K14AKT3MAPK8
SCHEMBL3474930 0.88 KCNH2 (0.38) CHEK1BRAFCDK8MAP3K14AKT3
SCHEMBL14612851 0.87 CDK5 (0.37) HDAC8HDAC6HDAC1ABL1AURKA
SCHEMBL14612877 0.86 ROCK2 (0.38) HDAC8HDAC6HDAC1CDK8AURKA
SCHEMBL14612878 0.85 MKNK1 (0.44) BRAFHDAC8MKNK1
SCHEMBL14612849 0.85 IKBKB (0.35) HDAC8IKBKBMAPK8MAPK9MAPK10
SCHEMBL13638501 0.85 HDAC8 (0.41) HDAC8HDAC6HDAC1ABL1AKT3
SCHEMBL13638286 0.85 ROCK2 (0.35) HDAC8HDAC6HDAC1IKBKBAURKA
SCHEMBL13638304 0.84 NQO2 (0.45) CHEK1BRAFHDAC6HDAC1ABL1
SCHEMBL13638579 0.84 SRC (0.35) IKBKBCHUKAKT3MAPK14MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK CHEK1 983/4885BRAF 317/4885HDAC8 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.